Benjamin Djulbegovic, MD, PhD
Researcher

Benjamin Djulbegovic, MD, PhD

View Lab Page

Overview

Dr. Djulbegovic studies research-synthesis, decision-analysis, medical uncertainty, evidence-based medicine, and methodology and ethics of clinical trials.

Discipline

    • Health Outcomes & Behavior Program

Education & Training

    • University of Sarajevo, MD
    • University of Zagreb, MSc - Biophysics
    • University of Belgrade, Resident - Internal Medicine
    • University of Sarajevo, Resident - Internal Medicine
    • University of Sarajevo, Fellow - Hematology
    • Paterson Institute for Cancer Research & Christie Hospital, Manchester, England, Fellow - Hematology
    • J.G. Brown Cancer Center, University of Louisville, Fellow - Hematology/Med. Oncology
    • University of Louisville, Resident - Internal Medicine
    • J.G. Brown Cancer Center, University of Louisville, Fellow - Hematology/Med. Oncology
    • University of Sarajevo, PhD
Research

Dr. Djulbegovic is a Distinguished Professor and Professor of Medicine and Oncology at the University of South Florida and Moffitt Cancer Center. His major academic research interests lie in the areas of evidence-based medicine, decision-analysis, clinical reasoning, systematic reviews/meta-analysis and comparative effectiveness research, ethics of clinical trials, practice guidelines, outcomes research, the impact of clinical trials and the role of uncertainty in medicine.  To date, Dr. Djulbegovic has published more than 190 papers in peer-review journals on these topics. 

Publications

  • Price AI, Djulbegovic B. What does evidence mean? Most languages translate "evidence" into "proof". J Eval Clin Pract. 2017 Oct;23(5):971-973. Pubmedid: 28960727.
  • Djulbegovic B, Elqayam S. Many faces of rationality: Implications of the great rationality debate for clinical decision-making. J Eval Clin Pract. 2017 Oct;23(5):915-922. Pubmedid: 28730671. Pmcid: PMC5655784.
  • Dahm P, Oxman AD, Djulbegovic B, Guyatt GH, Murad MH, Amato L, Parmelli E, Davoli M, Morgan RL, Mustafa RA, Sultan S, Falck-Ytter Y, Akl EA, Schünemann HJ. Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions. J Clin Epidemiol. 2017 Jun;86:129-139. Pubmedid: 28377194.
  • Mayrhofer T, Hamm RM, Van den Ende J, Hozo I, Djulbegovic B. The predicament of patients with suspected Ebola. Lancet Glob Health. 2017 Jul;5(7):e657. Pubmedid: 28619222.
  • Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017 Jul;390(10092):415-423. Pubmedid: 28215660.
  • Reljic T, Kumar A, Klocksieben FA, Djulbegovic B. Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review. BMJ Open. 2017 Jan;7(1):e014661. Pubmedid: 28062473. Pmcid: PMC5223692.
  • Hozo I, Djulbegovic B, Luan S, Tsalatsanis A, Gigerenzer G. Towards theory integration: Threshold model as a link between signal detection theory, fast-and-frugal trees and evidence accumulation theory. J Eval Clin Pract. 2017 Feb;23(1):49-65. Pubmedid: 26683386.
  • Hozo I, Tsalatsanis A, Djulbegovic B. Monte Carlo decision curve analysis using aggregate data. Eur J Clin Invest. 2017 Feb;47(2):176-183. Pubmedid: 28042671.
  • Djulbegovic B, Tsalatsanis A, Hozo I. Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. J Eval Clin Pract. 2017 Apr;23(2):241-250. Pubmedid: 26555150.
  • Tsalatsanis A, Hozo I, Djulbegovic B. Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations. Eur J Cancer. 2017 Apr;75:159-166. Pubmedid: 28235727.
  • Urrútia G, Ballesteros M, Djulbegovic B, Gich I, Roqué M, Bonfill X. Cancer randomized trials showed that dissemination bias is still a problem to be solved. J Clin Epidemiol. 2016 Sep;77:84-90. Pubmedid: 27164275.
  • Mhaskar R, Miladinovic B, Guterbock TM, Djulbegovic B. When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members. BMJ Open. 2016 Sep;6(9):e011150. Pubmedid: 27683511. Pmcid: PMC5051324.
  • Mhaskar R, Djulbegovic B. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents. JAMA Oncol. 2016 Nov;2(11):1499-1500. Pubmedid: 27387766.
  • Djulbegovic B, Tsalatsanis A, Mhaskar R, Hozo I, Miladinovic B, Tuch H. Eliciting regret improves decision making at the end of life. Eur J Cancer. 2016 Nov;68:27-37. Pubmedid: 27710829.
  • Bennett CL, Djulbegovic B. Thrombotic thrombocytopenic purpura: gaining knowledge. Lancet Haematol. 2016 May;3(5):e210-e211. Pubmedid: 27132693.
  • Cucchetti A, Djulbegovic B. Reply. Hepatology. 2016 Mar;63(3):1051. Pubmedid: 25976950.
  • Kumar A, Miladinovic B, Guyatt GH, Schünemann HJ, Djulbegovic B. GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE. J Clin Epidemiol. 2016 Jul;75:115-118. Pubmedid: 26845745.
  • Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. 2016 Feb;2:CD009624. Pubmedid: 26845108.
  • Martinez DA, Tsalatsanis A, Yalcin A, Zayas-Castro JL, Djulbegovic B. Activating clinical trials: a process improvement approach. Trials. 2016 Feb;17(1):106. Pubmedid: 26907923. Pmcid: PMC4765218.
  • Alexander PE, Li SA, Gionfriddo MR, Bero L, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Schünemann HJ, Guyatt GH. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. J Clin Epidemiol. 2016 Feb;70:123-128. Pubmedid: 26385188.
  • Alexander PE, Gionfriddo MR, Li SA, Bero L, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Norris SL, Schünemann HJ, Thabane L, Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Feb;70:111-122. Pubmedid: 26399903.
  • Hozo I, Tsalatsanis A, Djulbegovic B. Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account. J Eval Clin Pract. 2016 Dec. Pubmedid: 27981695.
  • Guyatt GH, Alonso-Coello P, Schünemann HJ, Djulbegovic B, Nothacker M, Lange S, Murad MH, Akl EA. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol. 2016 Dec;80:3-7. Pubmedid: 27452192.
  • Alexander PE, Brito JP, Neumann I, Gionfriddo MR, Bero L, Djulbegovic B, Stoltzfus R, Montori VM, Norris SL, Schünemann HJ, Guyatt GH. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Apr;72:98-106. Pubmedid: 25618534.
  • Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Ne. 2016 Apr;14(4):389-400. Pubmedid: 27059188.
  • Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2015 Nov;13(11):1398-1435. Pubmedid: 26553768. Pmcid: PMC4891187.
  • Gil-Herrera E, Aden-Buie G, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Rough set theory based prognostic classification models for hospice referral. BMC Med Inform Decis Mak. 2015 Nov;15:98. Pubmedid: 26606986. Pmcid: PMC4659220.
  • Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth AT, Djulbegovic B. Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 2015 May;55(5):1116-1127. Pubmedid: 25387589.
  • Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015 May;68(5):597-600. Pubmedid: 25660962.
  • Djulbegovic B, van den Ende J, Hamm RM, Mayrhofer T, Hozo I, Pauker SG. When is it rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation. Eur J Clin Invest. 2015 May;45(5):485-493. Pubmedid: 25675907.
  • Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, Cescon M, Ercolani G, Tuci F, Cillo U, Pinna AD. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology. 2015 Mar;61(3):905-914. Pubmedid: 25048515.
  • Djulbegovic B, Kumar A, Kaufman RM, Tobian A, Guyatt GH. Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation. J Clin Epidemiol. 2015 Jul;68(7):727-732. Pubmedid: 25766057.
  • Schully SD, Lam TK, Dotson WD, Chang CQ, Aronson N, Birkeland ML, Brewster SJ, Boccia S, Buchanan AH, Calonge N, Calzone K, Djulbegovic B, Goddard KA, Klein RD, Klein TE, Lau J, Long R, Lyman GH, Morgan RL, Palmer CG, Relling MV, Rubinstein WS, Swen JJ, Terry SF, Williams MS, Khoury MJ. Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genet Med. 2015 Jan;17(1):63-67. Pubmedid: 24946156. Pmcid: PMC4272332.
  • Djulbegovic B, Hozo I, Ioannidis JP. Modern health care as a game theory problem. Eur J Clin Invest. 2015 Jan;45(1):1-12. Pubmedid: 25413314.
  • Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, Sesok-Pizzini DA, Shander A, Stack GE, Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AA. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015 Feb;162(3):205-213. Pubmedid: 25383671.
  • Djulbegovic B, Hamm RM, Mayrhofer T, Hozo I, Van den Ende J. Rationality, practice variation and person-centred health policy: a threshold hypothesis. J Eval Clin Pract. 2015 Dec;21(6):1121-1124. Pubmedid: 26639018. Pmcid: PMC5064603.
  • Djulbegovic B. Value-Based Cancer Care and the Excessive Cost of Drugs. JAMA Oncol. 2015 Dec;1(9):1301-1302. Pubmedid: 26313294.
  • Mhaskar R, Pathak EB, Wieten S, Guterbock TM, Kumar A, Djulbegovic B. Those Responsible for Approving Research Studies Have Poor Knowledge of Research Study Design: a Knowledge Assessment of Institutional Review Board Members. Acta Inform Med. 2015 Aug;23(4):196-201. Pubmedid: 26483590. Pmcid: PMC4584095.
  • Reljic T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. Bone Marrow Transplant. 2015 Aug;50(8):1144. Pubmedid: 26242579.
  • Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control. 2015 Apr;22(2):235-241. Pubmedid: 26068771.
  • Djulbegovic B, Hozo I. Modern health care as a game theory problem: reply. Eur J Clin Invest. 2015 Apr;45(4):443. Pubmedid: 25630659.
  • Djulbegovic M, Beckstead J, Elqayam S, Reljic T, Kumar A, Paidas C, Djulbegovic B. Thinking Styles and Regret in Physicians. PLoS One. 2015;10(8):e0134038. Pubmedid: 26241650. Pmcid: PMC4524595.
  • Tsalatsanis A, Hozo I, Kumar A, Djulbegovic B. Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing. PLoS One. 2015;10(8):e0134800. Pubmedid: 26244571. Pmcid: PMC4526559.
  • Zhang Y, Tikkinen KA, Agoritsas T, Ayeni OR, Alexander P, Imam M, Yoo D, Tsalatsanis A, Djulbegovic B, Thabane L, Schünemann H, Guyatt GH. Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: a protocol for a multinational structured interview-based study combined with a randomised survey on the optimal amount of information to elicit preferences. BMJ Open. 2014 Oct;4(10):e005536. Pubmedid: 25326208. Pmcid: PMC4202002.
  • Wao H, Mhaskar R, Kumar A, Miladinovic B, Guterbock T, Hozo I, Djulbegovic B. Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies. Ann Epidemiol. 2014 Oct;24(10):734-740. Pubmedid: 25108689.
  • Djulbegovic B, Guyatt GH. Evidence-based practice is not synonymous with delivery of uniform health care. Jama. 2014 Oct;312(13):1293-1294. Pubmedid: 25268433.
  • Miladinovic B, Kumar A, Mhaskar R, Djulbegovic B. Benchmarks for detecting 'breakthroughs' in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation. BMJ Open. 2014 Oct;4(10):e005249. Pubmedid: 25335959. Pmcid: PMC4208055.
  • Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, Kumar A, Kharfan-Dabaja MA. Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. Biol Blood Marrow Tr. 2014 Nov;20(11):1677-1686. Pubmedid: 24867779.
  • Ioannidis JP, Hozo I, Djulbegovic B. Study design and the drug development process--reply. Jama. 2014 May;311(19):2023-2024. Pubmedid: 24846045.
  • Djulbegovic B. A framework to bridge the gaps between evidence-based medicine, health outcomes, and improvement and implementation science. J Oncol Pract. 2014 May;10(3):200-202. Pubmedid: 24839282.
  • Mhaskar RS, Reljic T, Wao H, Kumar A, Miladinovic B, Djulbegovic B. Treatment-related harms: what was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review. J Clin Epidemiol. 2014 Mar;67(3):354-356. Pubmedid: 24055164.
  • Djulbegovic B, Hozo I. Effect of initial conditions on reproducibility of scientific research. Acta Inform Med. 2014 Jun;22(3):156-159. Pubmedid: 25132705. Pmcid: PMC4130690.
  • Hernandez JM, Tsalatsanis A, Humphries LA, Miladinovic B, Djulbegovic B, Velanovich V. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Ann Surg. 2014 Jun;259(6):1208-1214. Pubmedid: 24169177.
  • Alexander PE, Bero L, Montori VM, Brito JP, Stoltzfus R, Djulbegovic B, Neumann I, Rave S, Guyatt G. World Health Organization recommendations are often strong based on low confidence in effect estimates. J Clin Epidemiol. 2014 Jun;67(6):629-634. Pubmedid: 24388966.
  • Djulbegovic B, Elqayam S, Reljic T, Hozo I, Miladinovic B, Tsalatsanis A, Kumar A, Beckstead J, Taylor S, Cannon-Bowers J. How do physicians decide to treat: an empirical evaluation of the threshold model. BMC Med Inform Decis Mak. 2014 Jun;14:47. Pubmedid: 24903517. Pmcid: PMC4055375.
  • Djulbegovic B, Beckstead J, Nash DB. Human judgment and health care policy. Popul Health Manag. 2014 Jun;17(3):139-140. Pubmedid: 24835387.
  • Mhaskar RS, Wao H, Mahony H, Kumar A, Djulbegovic B. Concordance between decision analysis and matching systematic review of randomized controlled trials in assessment of treatment comparisons: a systematic review. BMC Med Inform Decis Mak. 2014 Jul;14:57. Pubmedid: 25023450. Pmcid: PMC4107557.
  • Djulbegovic B, Beckstead JW, Elqayam S, Reljic T, Hozo I, Kumar A, Cannon-Bowers J, Taylor S, Tsalatsanis A, Turner B, Paidas C. Evaluation of Physicians' Cognitive Styles. Med Decis Making. 2014 Jul;34(5):627-637. Pubmedid: 24722474.
  • Pathak EB, Wieten S, Djulbegovic B. From hospice to hospital: short-term follow-up study of hospice patient outcomes in a US acute care hospital surveillance system. BMJ Open. 2014 Jul;4(7):e005196. Pubmedid: 25052170. Pmcid: PMC4120426.
  • Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014 Jul;(7):CD010280. Pubmedid: 25061777.
  • Reljic T, Mahony H, Djulbegovic B, Etchason J, Paxton H, Flores M, Kumar A. Value of repeat head computed tomography after traumatic brain injury: systematic review and meta-analysis. J Neurotrauma. 2014 Jan;31(1):78-98. Pubmedid: 23914924.
  • Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JP, Oliver S. How to increase value and reduce waste when research priorities are set. Lancet. 2014 Jan;383(9912):156-165. Pubmedid: 24411644.
  • Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014 Dec;(10):CD003039. Pubmedid: 25356786.
  • Gil-Herrera E, Tsalatsanis A, Kumar A, Mhaskar R, Miladinovic B, Yalcin A, Djulbegovic B. Identifying homogenous subgroups for individual patient meta-analysis based on Rough Set Theory. Conf Proc IEEE Eng Med Biol Soc. 2014 Aug;2014:3434-3437. Pubmedid: 25570729.
  • Mahony H, Tsalatsanis A, Kumar A, Djulbegovic B. Evolution of treatment regimens in multiple myeloma: a social network analysis. PLoS One. 2014;9(8):e104555. Pubmedid: 25119186. Pmcid: PMC4131914.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep;37(9):1077-1082. Pubmedid: 23809054.
  • Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, Hozo I, Tu D, Stanton HA, Booth CM, Meyer RM. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One. 2013 Oct;8(3):e58711. Pubmedid: 23555593. Pmcid: PMC3605423.
  • Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible?. Leuk Res Treatment. 2013 Nov;2013:629283. Pubmedid: 24288618. Pmcid: PMC3833187.
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Brit J Haematol. 2013 Nov;163(3):315-325. Pubmedid: 24033280.
  • Terasawa T, Trikalinos NA, Djulbegovic B, Trikalinos TA. Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. Cancer Treat Rev. 2013 May;39(4):340-349. Pubmedid: 22703832.
  • Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013 May;2:10. Pubmedid: 23379753. Pmcid: PMC3579762.
  • El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B, Kharfan-Dabaja MA. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy. 2013 May;5(5):457-466. Pubmedid: 23638742.
  • Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar;368(12):1131-1139. Pubmedid: 23514290. Pmcid: PMC3947590.
  • Miladinovic B, Kumar A, Hozo I, Mahony H, Djulbegovic B. Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials. Contemp Clin Trials. 2013 Mar;34(2):257-261. Pubmedid: 23274403.
  • Miladinovic B, Mhaskar R, Hozo I, Kumar A, Mahony H, Djulbegovic B. Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error. J Clin Epidemiol. 2013 Jun;66(6):654-659. Pubmedid: 23403248.
  • Calonge N, Fisher NL, Berg AO, Campos-Outcalt D, Djulbegovic B, Ganiats TG, Haddow JE, Klein RD, Lyman DO, Offit K, Pauker SG, Piper M, Richards CS, Strickland OL, Tunis SR, Veenstra DL. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. Genet Med. 2013 Jul;15(7):517-27. Pubmedid: 23429431.
  • Djulbegovic B, Norris LB, Bennett CL. Colony-stimulating factors for febrile neutropenia. N Engl J Med. 2013 Jul;369(3):286. Pubmedid: 23863062.
  • Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med. 2013 Jan;15(1):14-24. Pubmedid: 22955111. Pmcid: PMC3932295.
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple myeloma, version 1.2013. J Natl Compr Canc Ne. 2013 Jan;11(1):11-17. Pubmedid: 23307977.
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013 Jan;6:2. Pubmedid: 23289975. Pmcid: PMC3548722.
  • Mann H, Djulbegovic B. Comparator bias: why comparisons must address genuine uncertainties. J R Soc Med. 2013 Jan;106(1):30-33. Pubmedid: 23358277. Pmcid: PMC3556798.
  • Djulbegovic B, Hozo I. When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC Med Res Methodol. 2013 Feb;12:85. Pubmedid: 22726276. Pmcid: PMC3473303.
  • Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013 Dec;31(35):4387-4393. Pubmedid: 24190111.
  • Ioannidis JP, Hozo I, Djulbegovic B. Optimal type I and type II error pairs when the available sample size is fixed. J Clin Epidemiol. 2013 Sep;66(8):903-910.e2. Pubmedid: 23664493.
  • Djulbegovic B, Kumar A, Glasziou P, Miladinovic B, Chalmers I. Medical research: Trial unpredictability yields predictable therapy gains. Nature. 2013 Aug;500(7463):395-396. Pubmedid: 23969443. Pmcid: PMC3819120.
  • Mhaskar R, Alandikar V, Emmanuel P, Djulbegovic B, Patel S, Patel A, Naik E, Mohapatra S, Kumar A. Adherence to antiretroviral therapy in India: a systematic review and meta-analysis. Indian J Community Med. 2013 Apr;38(2):74-82. Pubmedid: 23878418. Pmcid: PMC3714945.
  • Miladinovic B, Kumar A, Mhaskar R, Kim S, Schonwetter R, Djulbegovic B. A flexible alternative to the Cox proportional hazards model for assessing the prognostic accuracy of hospice patient survival. PLoS One. 2013 Apr;7(10):e47804. Pubmedid: 23082220. Pmcid: PMC3474724.
  • Mhaskar R, Bercu B, Djulbegovic B. At what level of collective equipoise does a randomized clinical trial become ethical for the members of institutional review board/ethical committees?. Acta Inform Med. 2013;21(3):156-159. Pubmedid: 24167382. Pmcid: PMC3804473.
  • Miladinovic B, Mhaskar R, Kumar A, Kim S, Schonwetter R, Djulbegovic B. External validation of a web-based prognostic tool for predicting survival for patients in hospice care. J Palliative Care. 2013;29(3):140-146. Pubmedid: 24380212.
  • Djulbegovic B, Hozo I, Beckstead J, Tsalatsanis A, Pauker SG. Dual processing model of medical decision-making. BMC Med Inform Decis Mak. 2012 Sep;12:94. Pubmedid: 22943520. Pmcid: PMC3471048.
  • Kharfan-Dabaja MA, Pidala J, Kumar A, Terasawa T, Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant. 2012 Sep;47(9):1164-1170. Pubmedid: 22562081.
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Ne. 2012 Oct;10(10):1211-1219. Pubmedid: 23054875.
  • Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I. New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev. 2012 Oct;10:MR000024. Pubmedid: 23076962. Pmcid: PMC3490226.
  • Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012 May;10(5):628-653. Pubmedid: 22570293.
  • Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol. 2012 Jun;65(6):602-609. Pubmedid: 22424985. Pmcid: PMC3637913.
  • Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, Wang XF, Sargent DJ, Wickerham DL, Cronin W, Djulbegovic B, Slingluff CL. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res. 2012 Jan;18(1):256-262. Pubmedid: 21976533. Pmcid: PMC3977198.
  • La Caze A, Djulbegovic B, Senn S. What does randomisation achieve?. Evid Based Med. 2012 Feb;17(1):1-2. Pubmedid: 21693455.
  • Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012 Aug;(5):CD003188. Pubmedid: 22592688.
  • Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012 Apr;26(4):582-588. Pubmedid: 22182922.
  • Gil-Herrera E, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Towards a classification model to identify hospice candidates in terminally ill patients. Conf Proc IEEE Eng Med Biol Soc. 2012;2012:1278-1281. Pubmedid: 23366132.
  • Djulbegovic B. Uncertainty and equipoise: at interplay between epistemology, decision making and ethics. Am J Med Sci. 2011 Oct;342(4):282-289. Pubmedid: 21817885. Pmcid: PMC3183244.
  • Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011 Oct;(10):CD008818. Pubmedid: 21975786.
  • Schroen AT, Petroni GR, Wang H, Thielen MJ, Sargent D, Benedetti JK, Cronin WM, Wickerham DL, Wang XF, Gray R, Cohn WF, Slingluff CL, Djulbegovic B. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials. 2011 Oct;8(5):591-600. Pubmedid: 21878447. Pmcid: PMC3474201.
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct;9(10):1146-1183. Pubmedid: 21975914.
  • Djulbegovic B, Paul A. From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep. Jama. 2011 May;305(19):2005-2006. Pubmedid: 21586716.
  • Wager E, Mhaskar R, Warburton S, Djulbegovic B. JAMA published fewer industry-funded studies after introducing a requirement for independent statistical analysis. PLoS One. 2011 Mar;5(10):e13591. Pubmedid: 21042585. Pmcid: PMC2962640.
  • Tsalatsanis A, Barnes L, Hozo I, Skvoretz J, Djulbegovic B. A social network analysis of treatment discoveries in cancer. PLoS One. 2011 Mar;6(3):e18060. Pubmedid: 21464896. Pmcid: PMC3065482.
  • Dahm P, Djulbegovic B. The Australian 'FORM' approach to guideline development: the quest for the perfect system. BMC Med Res Methodol. 2011 Jun;11:17. Pubmedid: 21324126. Pmcid: PMC3055217.
  • Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol. 2011 Jun;64(6):583-593. Pubmedid: 21163620. Pmcid: PMC3079810.
  • Kumar A, Galeb S, Djulbegovic B. Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta Haematol. 2011 Jan;125(1-2):8-22. Pubmedid: 21150183.
  • Gil-Herrera E, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Rough Set Theory based prognostication of life expectancy for terminally ill patients. Conf Proc IEEE Eng Med Biol Soc. 2011 Jan;2011:6438-6441. Pubmedid: 22255812.
  • Kumar A, Hozo I, Wheatley K, Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol. 2011 Jan;86(1):18-24. Pubmedid: 21120867.
  • Djulbegovic M, Djulbegovic B. Implications of the principle of question propagation for comparative-effectiveness and "data mining" research. Jama. 2011 Jan;305(3):298-299. Pubmedid: 21245185.
  • Tsalatsanis A, Gil-Herrera E, Yalcin A, Djulbegovic B, Barnes L. Designing patient-centric applications for chronic disease management. Conf Proc IEEE Eng Med Biol Soc. 2011 Jan;2011:3146-3149. Pubmedid: 22255007.
  • Tsalatsanis A, Barnes LE, Hozo I, Djulbegovic B. Extensions to regret-based decision curve analysis: an application to hospice referral for terminal patients. BMC Med Inform Decis Mak. 2011 Dec;11:77. Pubmedid: 22196308. Pmcid: PMC3305393.
  • Miladinovic B, Kumar A, Hozo I, Djulbegovic B. Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance. BMC Med Res Methodol. 2011 Apr;11:55. Pubmedid: 21510899. Pmcid: PMC3117817.
  • Tsalatsanis A, Hozo I, Vickers A, Djulbegovic B. A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making. BMC Med Inform Decis Mak. 2010 Sep;10:51. Pubmedid: 20846413. Pmcid: PMC2954854.
  • Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. Bmj. 2010 Sep;341:c4543. Pubmedid: 20843937. Pmcid: PMC2939952.
  • Djulbegovic B. Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. J Support Oncol. 2010 Mar;8(2):84-91. Pubmedid: 20464888.
  • Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. Jama. 2010 Mar;303(12):1180-1187. Pubmedid: 20332404.
  • Herold CI, Djulbegovic B, Hozo I, Lyman GH. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Res Treat. 2010 Jun;121(3):771-776. Pubmedid: 19806449.
  • Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2010 Feb;95(2):340-342. Pubmedid: 19850902. Pmcid: PMC2817042.
  • Roback JD, Murad MH, Djulbegovic B. In reply. Transfusion. 2010 Dec;50(12):2763-2764. Pubmedid: 21126253.
  • Mhaskar AR, Quinn G, Vadaparampil S, Djulbegovic B, Gwede CK, Kumar A. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials. Cancer Treat Rev. 2010 Dec;36(8):621-628. Pubmedid: 20444550.
  • Schroen AT, Petroni GR, Hongkun Wang, Gray R, Wang XF, Cronin WM, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials. 2010 Aug;7(4):312-321. Pubmedid: 20595245. Pmcid: PMC3977321.
  • Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2010 Apr;(3):CD003188. Pubmedid: 20238320.
  • Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Tr. 2009 Sep;15(9):1005-1013. Pubmedid: 19660713.
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct;7(9):908-942. Pubmedid: 19878637.
  • Djulbegovic B. The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research. Cancer Control. 2009 Oct;16(4):342-347. Pubmedid: 19910921. Pmcid: PMC2782889.
  • Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2009 Nov;15(11):1415-1421. Pubmedid: 19822301.
  • Djulbegovic B, Trikalinos TA, Roback J, Chen R, Guyatt G. Impact of quality of evidence on the strength of recommendations: an empirical study. BMC Health Serv Res. 2009 Nov;9:120. Pubmedid: 19622148. Pmcid: PMC2722589.
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009 May;373(9674):1532-1542. Pubmedid: 19410717.
  • Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009 Jun;27(18):3036-3043. Pubmedid: 19414675. Pmcid: PMC3646306.
  • Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun;15(11):3850-3855. Pubmedid: 19458059. Pmcid: PMC3296235.
  • Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. Jama. 2009 Jun;301(22):2349-2361. Pubmedid: 19509382. Pmcid: PMC3163846.
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009 Jul;(3):CD007303. Pubmedid: 19588423.
  • Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schünemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials. 2009 Jul;10:49. Pubmedid: 19580665. Pmcid: PMC2723099.
  • Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009 Jan;101(2):100-106. Pubmedid: 19141779.
  • Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant. 2009 Aug;15(8):893-902. Pubmedid: 19589478.
  • Djulbegovic B, Guyatt GH, Ashcroft RE. Epistemologic inquiries in evidence-based medicine. Cancer Control. 2009 Apr;16(2):158-168. Pubmedid: 19337202.
  • Djulbegovic B, Kumar A. Multiple myeloma: detecting the effects of new treatments. Lancet. 2008 May;371(9625):1642-1644. Pubmedid: 18486726.
  • Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med. 2008 Mar;168(6):632-642. Pubmedid: 18362256. Pmcid: PMC2773511.
  • Fletcher J, Djulbegovic B, Soares H, Siegel B, Lowe V, Lyman G, ColemanRE, Wahl R, Paschold J, Avril N, Einhorn L, Suh W, Samson D, Delbeke D, GormanM, Shields A. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008 Mar;49(3):480-508. Pubmedid: 18287273.
  • Hozo I, Schell M, Djulbegovic B. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol. 2008 Jul;45(3):150-159. Pubmedid: 18582621.
  • Hozo I, Djulbegovic B. When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach. Med Decis Making. 2008 Jul;28(4):540-553. Pubmedid: 18480041.
  • Wilcox R, Djulbegovic B, Moffitt H, Guyatt G, Montori V. Randomized trials in oncology stopped early for benefit. J Clin Oncol. 2008 Jan;26(1):18-9. Review. Pubmedid: 18165635.
  • Rizzo JP, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan;26(1):132-149. Pubmedid: 17954713.
  • Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan;111(1):25-41. Pubmedid: 17954703.
  • Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Jama. 2008 Feb;299(8):914-924. Pubmedid: 18314434.
  • Kharfan-Dabaja M, Kumar A, Behera M, Djulbegovic B. Systematic review of high dose chemotherapy and autologous haematopoietic stemcell transplantation for chronic lymphocytic leukaemia: what is the publishedevidence. Br J Haematol. 2007 Oct;139(2):234-242. Pubmedid: 17897299.
  • Bennett C, Nebeker J, Yarnold P, Tigue C, Dorr D, McKoy J, Edwards B, Hurdle J, West D, Lau D, Angelotta C, Weitzman S, Belknap S, Djulbegovic B, Tallman M, Kuzel T, Benson A, Evens A, Trifilio S, Courtney D, Raisch D. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007 May;167(10):1041-1049. Pubmedid: 17533207.
  • Djulbegovic B. Articulating and responding to uncertainties in clinical research. J Med Philos. 2007 Mar;32(2):79-98. Pubmedid: 17454416.
  • Djulbegovic B, Hozo I. When should potentially false research findings be considered acceptable?. PLoS Med. 2007 Feb;4(2):e26. Pubmedid: 17326703. Pmcid: PMC1808081.
  • Anderson K, Alsina M, Bensinger W, Biermann J, Chanan-Khan A, Comenzo R, De Castro C, Djulbegovic B, Farag S, Huff C, Meredith R, Schriber J, ShrieveD, Singhal S, Smith M, Stockerl-Goldstein K, Vose J, Weber D, Yahalom J, YunusF. Multiple myeloma guidelines. J Natl Compr Canc Netw. 2007 Feb;5(2):118-147. Pubmedid: 17335683.
  • Soares H, Kumar A, Djulbegovic B. Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev. 2007 Feb;33(1):87-89. Pubmedid: 17081695.
  • Koreth J, Cutler C, Djulbegovic B, Behl R, Schlossman R, Munshi N, Richardson P, Anderson K, Soiffer R, Alyea EP 3rd. High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Biol Blood Marrow Transplant. 2007 Feb;13(2):183-196. Pubmedid: 17241924.
  • Djulbegovic B, Hozo I, Lyman G. Estimating net benefits and harms of screening mammography in women age 40 to 49 years. Ann Intern Med. 2007 Dec;147(12):882-882. Pubmedid: 18087062.
  • Tanvetyanon T, Soares H, Djulbegovic B, Jacobsen P, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1091-1097. Pubmedid: 18090580.
  • Djulbegovic B, Angelotta C, Knox K, Bennett C. The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol. 2007 Aug;25(24):3567-3569. Pubmedid: 17704401.
  • Kumar A, Soares H, Balducci L, Djulbegovic B. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007 Apr;25(10):1272-1276. Pubmedid: 17401017.
  • Behera M, Kumar A, Soares H, Sokol L, Djulbegovic B. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control. 2007 Apr;14(2):160-166. Pubmedid: 17387301.
  • Scheetz MH, McKoy JM, Parada J, Djulbegovic B, Raisch D, Yarnold PR, Zagory J, Trifilio S, Jakiche R, Palella F, Kahn A, Chandler K, Bennett CL. Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007;30(4):295-306. Pubmedid: 17408306.
  • Fisher R, Bernstein S, Kahl B, Djulbegovic B, Robertson M, de Vos S, Epner E, Krishnan A, Leonard J, Lonial S, Stadtmauer E, O'Connor O, Shi H, Boral A, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006 Oct;24(30):4867-4874. Pubmedid: 17001068.
  • Kumar A, Soares H, Djulbegovic B. Evidence profiles for colo-rectal cancer: Benefit/harms data based on the totality of randomized evidence. 2006 Nov;32(7):577-580. Pubmedid: 16919883.
  • Djulbegovic B, Soares H, Kumar A. What kind of evidence do patients and practitioners need: Evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. 2006 Nov;32(7):572-576. Pubmedid: 16914268.
  • Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May;98(10):708-714. Pubmedid: 16705125.
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 3 November to 24 November, 2005: A summary. Cancer Treat Rev. 2006 May;32(3):239-241. Pubmedid: 16624491.
  • Prentice A, Glasmacher A, Djulbegovic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis ofsystemic fungal infection in the treatment of haematological malignancy. Br J Haematol. 2006 Mar;132(5):656-8. Pubmedid: 16445845.
  • Kumar A, Djulbegovic B. Multiple myeloma. Clin Evid. 2006 Jun;(15):1-29. Pubmedid: 16973003.
  • Pavlidis N, Stahel R, Clarke M, Djulbegovic B. Cancer treatment reviews welcomes submission of the Cochrane Reviews. Cancer Treat Rev. 2006 Jun;32(4):243-244. Pubmedid: 16713102.
  • Glasziou P, Djulbegovic B, Burls A. Are systematic reviews more cost-effective than randomised trials. Lancet. 2006 Jun;367(9528):2057-2058. Pubmedid: 16798380.
  • Djulbegovic B. Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. J Eval Clin Pract. 2006 Jun;12(3):257-259. Pubmedid: 16722903.
  • Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett C, Langensiepen S, Hyde C, Engert E. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006 Jul;3:CD003407-CD003407. Pubmedid: 16856007.
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 16 June to 18 August 2005: A summary. Cancer Treat Rev. 2006 Feb;32(1):59-64. Pubmedid: 16434143.
  • Djulbegovic B, Lyman G. Screening mammography at 40-49 years: regret or no regret?. Lancet. 2006 Dec;368(9552):2035-2037. Pubmedid: 17161713.
  • Soares H, Kumar A, Djulbegovic B. Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev. 2006 Dec;32(8):652-655. Pubmedid: 17008011.
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 25 August to 27 October 2005: A summary. Cancer Treat Rev. 2006 Apr;32(2):149-155. Pubmedid: 16520003.
  • Djulbegovic B, Frohlich A, Bennett C. Acting on imperfect evidence: how much regret are we ready to accept?. J Clin Oncol. 2005 Oct;23(28):6822-6825. Pubmedid: 16145058.
  • Rodgers GM 3rd, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia P, Demetri G, Djulbegovic B, Garst J, Gore M, Kraut E, Lin W, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P. Cancer- and treatment-related anemia. J Natl Compr Canc Netw. 2005 Nov;3(6):772-789. Pubmedid: 16316613.
  • Clark O, Lyman G, Castro A, Clark L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005 Jun;23(18):4198-4214. Pubmedid: 15961767.
  • Vincent S, Djulbegovic B. Oncology treatment recommendations can be supported only by 1-2% of high-quality published evidence. Cancer Treat Rev. 2005 Jun;31(4):319-322. Pubmedid: 16006047.
  • Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments?. Jama. 2005 Feb;293(8):970-978. Pubmedid: 15728168. Pmcid: PMC1779758.
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 22nd June to 26th August 2004: a summary. Cancer Treat Rev. 2005 Feb;31(1):63-67. Pubmedid: 15707707.
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 19 May to 9 June 2005: A summary. Cancer Treat Rev. 2005 Dec;31(8):653-656. Pubmedid: 16298072.
  • Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. Bmj. 2005 Dec;331(7528):1295. Pubmedid: 16299015. Pmcid: PMC1298846.
  • Lyman G, Djulbegovic B. The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treat Rev. 2005 Dec;31(8):628-639. Pubmedid: 16225994.
  • Djulbegovic B, Kumar A. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005 Aug;23(22):5074-5087. Pubmedid: 16051954.
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 1st September to 14th October 2004: a summary. Cancer Treat Rev. 2005 Apr;31(2):155-157. Pubmedid: 15847985.
  • Djulbegovic B. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best Pract Res Clin Haematol. 2005;18(3):455-466. Pubmedid: 15792920.
  • Hozo I, Djulbegovic B, Clark O, Lyman GH. Use of re-randomized data in meta-analysis. BMC Med Res Methodol. 2005;5:17. Pubmedid: 15882470. Pmcid: PMC1145185.
  • Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. Pubmedid: 15840177. Pmcid: PMC1097734.
  • Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May;103(9):3271-3277. Pubmedid: 14726402.
  • Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. Bmj. 2004 Jan;328(7430):22-24. Pubmedid: 14703540. Pmcid: PMC313900.
  • Djulbegovic B. Lifting the fog of uncertainty from the practice of medicine. BMJ. 2004 Dec;329(7480):1419-1420. Pubmedid: 15604164. Pmcid: PMC535956.
  • Djulbegovic B. Well informed uncertainties about the effects of treatment: paradox exists in dealing with uncertainty. BMJ. 2004 Apr;328(7446):1018. Pubmedid: 15105342. Pmcid: PMC404547.
  • Djulbegovic B, Vincent S. High-quality evidence in oncology from 20th April to 11th May 2004: a summary. Cancer Treat Rev. 2004;30(7):665-667. Pubmedid: 15531400.
  • Djulbegovic B. Where is the evidence. Eur J Cancer. 2004;40(18):2637-2637. Pubmedid: 15648121.
  • Durie B, Kyle R, Belch A, Bensinger W, Blade J, Boccadoro M, Child J, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau J, Hungria V, JoshuaD, Ludwig H, Mehta J, Morales A, Morgan G, Nouel A, Oken M, Powles R, RoodmanD, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van NessB. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2004;4:379-398. Pubmedid: 14671610.
  • Djulbegovic B, Vincent S. High-quality evidence in oncology from 18th May to 15th June 2004: a summary. Cancer Treat Rev. 2004;30(8):721-723. Pubmedid: 15541583.
  • Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May;326(7400):1167-1170. Pubmedid: 12775614. Pmcid: PMC156458.
  • Kumar A, Loughran T, Alsina M, Durie B, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. 2003 May;4(5):293-304. Pubmedid: 12732167.
  • Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf I. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003 Dec;21(24):4615-4626. Pubmedid: 14673051.
  • Mann H, Djulbegovic B. Choosing a control intervention for a randomised clinical trial. BMC Med Res Methodol. 2003 Apr;3:7. Pubmedid: 12709266. Pmcid: PMC165581.
  • Mann H, Djulbegovic B. Off-study availability of investigational treatments. Lancet. 2003 Apr;361(9365):1302. Pubmedid: 12699986.
  • Mann H, Djulbegovic B. Clinical equipoise and the therapeutic misconception. Hastings Cent Rep. 2003;33(5):4-5. Pubmedid: 14696270.
  • Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, ZiskeC, Schmidt-Wolf I. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica. 2003;88(11):1304-1315. Pubmedid: 14607760.
  • Djulbegovic B, Singh D. Evidence-based oncology section - aims and scope. Cancer Treat Rev. 2003;29(1):51-53. Pubmedid: 12633580.
  • Singh D, Djulbegovic B. Evidence-based Oncology section--policies and scope. Cancer Treat Rev. 2003;29(2):121-122. Pubmedid: 12670454.
  • Mann H, Djulbegovic B, Gold P. Failure of equipoise to resolve the ethical tension in a randomized clinical trial. J Law Med Ethics. 2003;31(1):5-6. Pubmedid: 12762098.
  • He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev. 2003;4023-4023. Pubmedid: 12535504.
  • Djulbegovic B, Seidenfeld J, Bonnell C, Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review. Cancer Control. 2003;10(1):17-41. Pubmedid: 12598853.
  • Djulbegovic B, Coleman R, Stahel R, Singh D, Lyman G. Evidence-based oncology in cancer treatment reviews. Cancer Treat Rev. 2003;29(1):45-50. Pubmedid: 12633579.
  • Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Account Res. 2003;10(4):301-315. Pubmedid: 14989285.
  • Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer. 2002 Sep;2:23. Pubmedid: 12270068. Pmcid: PMC130027.
  • Bottomley A, Thomas R, Van Steen K, Flechtner H, Djulbegovic B. Erythropoietin improves quality of life--a response. Lancet Oncol. 2002 Sep;3(9):527. Pubmedid: 12217788.
  • Gordon M, Lichtin A, Woolf S, Rizzo D, Seidenfeld J, Bennett B, Cella D, Djulbegovic B, Goode M, Jakubowski A, Lee S, Miller C, Rarick M, Regan D. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002 Oct;20(19):4083-4107. Pubmedid: 12351606.
  • Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002 Oct;100(7):2303-2320. Pubmedid: 12239138.
  • Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncol. 2002 Mar;3(3):145-153. Pubmedid: 11902500.
  • Djulbegovic B. Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ. 2002 Dec;325(7377):1420. Pubmedid: 12480865.
  • Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002 Apr;112(5):406-411. Pubmedid: 11904116.
  • Wheatley K, Djulbegovic B, Glasmacher A. Priority-setting decisions for new cancer drugs. Lancet. 2002 Apr;359(9316):1525. Pubmedid: 11988282.
  • Djulbegovic B, Hozo I. At what degree of belief in a research hypothesis is a trial in humans is justified?. J Eval Clin Pract. 2002;8(2):269-276. Pubmedid: 12180373.
  • Cruse H, Winiarek M, Marshburn J, Clark O, Djulbegovic B. Quality and methods of developing practice guidelines. BMC Health Serv Res. 2002;2:1. Pubmedid: 11825346. Pmcid: PMC65517.
  • Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. Curr Oncol Rep. 2001 Sep;3(5):389-395. Pubmedid: 11489238.
  • Djulbegovic B, Clarke M. Scientific and ethical issues in equivalence clinical trials. Jama. 2001;285(9):1206-1208. Pubmedid: 11231752.
  • Djulbegovic B, Adams J, Lyman G, Lacevic M, Hozo I, Greenwich M, BennettCL. Evaluation and appraisal of randomized controlled trials in myeloma. Ann Oncol. 2001;12(11):1611-1617. Pubmedid: 11822763.
  • Lilford R, Djulbegovic B. Declaration of Helsinki should be strengthened. Equipoise is essential principle of human experimentation. Bmj. 2001;322(7281):299-300. Pubmedid: 11157551.
  • Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Bisphosphonates in multiple myeloma. Cochranedatabase Syst Rev. 2001;(4):3188-3188. Pubmedid: 11687178.
  • Djulbegovic B, Clark M. Ethical Issues in the reporting of clinical trials. Jama. 2001;286(13):1577-1578. Pubmedid: 11585477.
  • Djulbegovic B, Cohen Y. The natural history of refractory idiopathic thrombocytopenic pupura. Blood. 2001;98(7):2282-2283. Pubmedid: 11592263.
  • Djulbegovic B. Placebo-controlled trials. Ann Intern Med. 2001;135(1):62-63. Pubmedid: 11434740.
  • Lilford R, Djulbegovic B. Uncertainty about clinical equipoise. Equipose and uncertainty principle are not mutually exclusive. Bmj. 2001;795(7289):795-795. Pubmedid: 11322146.
  • Djulbegovic B, Lacevic M, Cantor A, Fields K, Bennett-Tate C, Adams J, Kuderer N, Lyman G. The uncertainty principle and industry-sponsored research. Lancet. 2000 Aug;356(9230):635-638. Pubmedid: 10968436.
  • Djulbegovic B, Morris L, Lyman G. Evidentiary challenges to evidence-based medicine. J Eval Clin Pract. 2000;6(2):99-109. Pubmedid: 10970004.
  • Cohen Y, Djulbegovic B, Shamai O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630-1638. Pubmedid: 10847256.
  • Djulbegovic B. Acquired anaemias and polycythaemia. Lancet. 2000;356:596-596. Pubmedid: 10950261.
  • Djulbegovic B, Hozo I, Lyman G. Talking about treatment. Ann Intern Med. 2000;132(1):94-94. Pubmedid: 10627263.
  • Knox K, Adams J, Djulbegovic B, Stinson T, Bennett-Tate C. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol. 2000;11(12):1591-1595. Pubmedid: 11205468.
  • Djulbegovic B, Hozo I, Lyman G. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. Medgenmed. 2000;2(1):E6-E6. Pubmedid: 11104452.
  • Djulbegovic B, Hozo I, Schwartz A, McMasters KM. Acceptable regret in medical decision making. Med Hypotheses. 1999 Sep;53(3):253-259. Pubmedid: 10580533.
  • Hozo I, Djulbegovic B. Using internet to Calculate Clinical Action Tresholds. Comput Biomed Res. 1999 Apr;32(2):168-185. Pubmedid: 10337498.
  • Djulbegovic B, Hendler F, Pavletic S. Reasoning by identifying goals of treatment. Cancer Control. 1999;6:3 77-384. Pubmedid: 10758570.
  • Djulbegovic B, Loughran, Jr. T, Kloecker G, Efthimiadis E, Hadley T, Englert J, Hoskins M, Goldsmith G. A status of the quality of medical evidence in hematology/oncology. Am J Med. 1999;106:198-205. Pubmedid: 10230750.
  • Djulbegovic B, Hozo I. Computer program for the diagnosis and treatment of polycythemia rubra vera. Md Computing. 1999;16:83-89. Pubmedid: 10202430.
  • Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999;5:3734s-3734s.
  • Hozo I, Djulbegovic B. Calculating confidence intervals for threshold and posttest probabilities. Md Computing. 1998;15:110-115. Pubmedid: 9540324.
  • Djulbegovic B, Hozo I, Fields K, Sullivan D. High-dose chemotherapy in the adjuvant treatment of breast cancer: benefit risk analysis. Cancer Control. 1998;5:394-405. Pubmedid: 10761089.
  • Djulbegovic B, Hadley T. The need and feasibility of evidence-based guidelines in oncology. Oncology. 1998;12:310-314. Pubmedid: 10028514.
  • Djulbegovic B, Goldsmith G, Vaughn D, Birkimer J, Marasa M, Joseph G, Huang A, Hadley T. Comparison of the quality of life between HIV positive hemophilia patients and HIV negative hemophilia patients. Haemophilia. 1996;2:166-172.
  • Djulbegovic B, Desoky A. Equation and nomogram for calculation of testing and treatment thresholds. Med Decis Making. 1996;16:198-199. Pubmedid: 8778540.
  • Djulbegovic B, Marasa M, Pesto A, Kushner GM, Hadley T, Joseph G, Goldsmith G. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol. 1996;51:168-170. Pubmedid: 8579061.
  • Cervera A, Djulbegovic B. Acute myelogenous leukemia. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management. New York, NY: Churchill Livingstone; 1997;29-36.
  • Djulbegovic B. T-cell lymphoma. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;91-102.
  • Mangino P, Taft B, Djulbegovic B. Treatment protocol in oncology. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;453-532.
  • Djulbegovic B, Hozo I, Ioannidis JP. Improving the drug development process: more not less randomized trials. Jama. 311(4):355-356. Pubmedid: 24449311.
  • Djulbegovic B. Principles of reasoning and decision making in oncology. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;1-14.
  • Kumar A, Djulbegovic B. Why evidence based oncology management. J Oncol Manag. 11(6):13-16. Pubmedid: 12502287.
  • Djulbegovic B. Reasoning and Decision Making in Hematology. New York, NY: Churchill Livingstone; 1992.
  • Djulbegovic B. Chronic lymphocytic leukemia. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;45-52.
  • Clark O, Lyman G, Castro A, Clark L, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. In: The cochrane library. Oxford. Update Software Cochrane; 2003.
  • Yam L, Djulbegovic B. Hodgkin's disease. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management. New York, NY: Churchill Livingstone; 1997;57-68.
  • Djulbegovic B. NonHodgkin's lymphoma. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management. New York, NY: Churchill Livingstone; 1997;69-90.
  • Bepler G, Goodridge Carney D, Djulbegovic B, Clark R, Tockman M. A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. Cancer Control. 10(4):306-314. Pubmedid: 12915809.
  • Beganovic B, Djulbegovic B. Plasma cell disorders. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;103-114.
  • Djulbegovic B. Chronic myelogenous leukemia. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;37-44.